Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Isabel Achatz

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Journal of Psychosocial Oncology|December 29, 2018
Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independenceJennifer L Young, Ashley Pantaleao, Lori Zaspel, et al.
Cancer Genetics|January 30, 2016
Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndromeGabriel S Macedo, Igor Araujo Vieira, Ana Paula Brandalize, et al.
Iscience|December 5, 2024
Clustering of <i>TP53</i> variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndromeEmilie Montellier, Nathanaël Lemonnier, Judith Penkert, et al.
Cancer Medicine|March 26, 2018
Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch SyndromeNayê Balzan Schneider, Tatiane Pastor, André Escremim de Paula, et al.
International Journal of Molecular Sciences|October 28, 2023
The Clinical and Molecular Profile of Lung Cancer Patients Harboring the <i>TP53</i> R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of CarcinogenesisCarlos D H Lopes, Fernanda F Antonacio, Priscila M G Moraes, et al.
Human Mutation|September 2, 2017
Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer historyKelvin César de Andrade, Lisa Mirabello, Douglas R Stewart, et al.
Familial Cancer|July 31, 2017
p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriersGabriel S Macedo, Igor Araujo Vieira, Fernanda Salles Luiz Vianna, et al.
Plos One|February 19, 2021
Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysisRenata Lazari Sandoval, Ana Carolina Rathsam Leite, Daniel Meirelles Barbalho, et al.
Familial Cancer|January 8, 2015
The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriersMariana Fitarelli-Kiehl, Juliana Giacomazzi, Patricia Santos-Silva, et al.
BMC Cancer|May 8, 2019
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genesAlexandre A B A da Costa, Luisa M do Canto, Simon Jonas Larsen, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Journal of Psychosocial Oncology|December 29, 2018
Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independenceJennifer L Young, Ashley Pantaleao, Lori Zaspel, et al.
Cancer Genetics|January 30, 2016
Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndromeGabriel S Macedo, Igor Araujo Vieira, Ana Paula Brandalize, et al.
Iscience|December 5, 2024
Clustering of <i>TP53</i> variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndromeEmilie Montellier, Nathanaël Lemonnier, Judith Penkert, et al.
Cancer Medicine|March 26, 2018
Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch SyndromeNayê Balzan Schneider, Tatiane Pastor, André Escremim de Paula, et al.
International Journal of Molecular Sciences|October 28, 2023
The Clinical and Molecular Profile of Lung Cancer Patients Harboring the <i>TP53</i> R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of CarcinogenesisCarlos D H Lopes, Fernanda F Antonacio, Priscila M G Moraes, et al.
Human Mutation|September 2, 2017
Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer historyKelvin César de Andrade, Lisa Mirabello, Douglas R Stewart, et al.
Familial Cancer|July 31, 2017
p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriersGabriel S Macedo, Igor Araujo Vieira, Fernanda Salles Luiz Vianna, et al.
Plos One|February 19, 2021
Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysisRenata Lazari Sandoval, Ana Carolina Rathsam Leite, Daniel Meirelles Barbalho, et al.
Familial Cancer|January 8, 2015
The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriersMariana Fitarelli-Kiehl, Juliana Giacomazzi, Patricia Santos-Silva, et al.
BMC Cancer|May 8, 2019
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genesAlexandre A B A da Costa, Luisa M do Canto, Simon Jonas Larsen, et al.
Pageof 8